Standigm, Inc. and Ajou university medical center today have signed a Memorandum of Understanding (MOU) for developing drug discovery and improving clinical trials using artificial intelligence technology.

Seoul, Korea, South, June 01, 2017 –(PR.com)– CrystalGenomics, Inc. (KOSDAQ: 083790) and Standigm, Inc., today announced the collaborative partnership to apply Artificial Intelligence (AI) to the research and development of novel drugs.

Standigm, Inc. and CrystalGenomics, Inc. today agree collaborative partnership with the objective to discover and develop first-in-class drugs in the multiple therapeutic areas including cancer, rheumatoid arthritis and liver related diseases.

Jinhan Kim, Standigm CEO, spoke about StandigmAI, the drug repositioning solution, in the Precision Medicine World Conference (PMWC) Silicon Valley.

Standigm, Inc. today announced that it has raised $3 million (3.4 billion won) in seed funding from three capital firms: K-Cube Ventures LLC, LB Investment, Inc., and Autism Investment Co., Ltd.